Contact
searchSearch
HMP Global

Volume 33 - Issue 3 - March, 2021

Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis
Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis
03/01/2021
Polymer-free (PF) drug-eluting stent (DES) devices have a proven benefit over bare-metal stent (BMS) devices in previous trials. It is unknown, however, whether polymer-based (PB)-DES devices are as safe as PF-DES devices.
Polymer-free (PF) drug-eluting stent (DES) devices have a proven benefit over bare-metal stent (BMS) devices in previous trials. It is unknown, however, whether polymer-based (PB)-DES devices are as safe as PF-DES devices.
Polymer-free (PF) drug-eluting...
03/01/2021
Journal of Invasive Cardiology
In-Hospital and 30-Day Mortality After Percutaneous Coronary Intervention in England in the Pre-COVID and COVID Eras
In-Hospital and 30-Day Mortality After Percutaneous Coronary Intervention in England in the Pre-COVID and COVID Eras
03/01/2021
Abstract
Abstract
Abstract
03/01/2021
Journal of Invasive Cardiology
Accidental Cannulation of the Cardiac Venous System During Pericardiocentesis
Accidental Cannulation of the Cardiac Venous System During Pericardiocentesis
03/01/2021
A 52-year-old woman presented to another hospital with progressive dyspnea of 10-day duration. This case underscores the importance of image-guided pericardiocentesis.
A 52-year-old woman presented to another hospital with progressive dyspnea of 10-day duration. This case underscores the importance of image-guided pericardiocentesis.
A 52-year-old woman presented to...
03/01/2021
Journal of Invasive Cardiology
Treating Mitral Valve Prolapse in Barlow’s Disease by Creation of a Medial MitraClip Bridge and a “New” Lateral Orifice: Rationale for MitraClip NTR Adoption
Treating Mitral Valve Prolapse in Barlow’s Disease by Creation of a Medial MitraClip Bridge and a “New” Lateral Orifice: Rationale for MitraClip NTR Adoption
03/01/2021
We summarize our rationale for using the shorter and smaller MitraClip NTR in patients with Barlow’s disease.
We summarize our rationale for using the shorter and smaller MitraClip NTR in patients with Barlow’s disease.
We summarize our rationale for...
03/01/2021
Journal of Invasive Cardiology
Percutaneous Management of a Mechanical Complication Post Mitral Valve Surgery in a Child
Percutaneous Management of a Mechanical Complication Post Mitral Valve Surgery in a Child
03/01/2021
A 4-year-old girl with congenital mitral regurgitation status post mechanical mitral valve replacement (MVR) using a 16 mm Carbomedics valve (LivaNova) at the age of 5 months underwent a redo MVR.
A 4-year-old girl with congenital mitral regurgitation status post mechanical mitral valve replacement (MVR) using a 16 mm Carbomedics valve (LivaNova) at the age of 5 months underwent a redo MVR.
A 4-year-old girl with...
03/01/2021
Journal of Invasive Cardiology
De Winter Pattern Caused by a Large Diagonal Branch Culprit Lesion
De Winter Pattern Caused by a Large Diagonal Branch Culprit Lesion
03/01/2021
The De Winter pattern should be promptly recognized and lead to the same approach (such as immediate coronary angiography) of an anterior ST-segment elevation pattern.
The De Winter pattern should be promptly recognized and lead to the same approach (such as immediate coronary angiography) of an anterior ST-segment elevation pattern.
The De Winter pattern should be...
03/01/2021
Journal of Invasive Cardiology
Giant Aortic Root Aneurysm in Marfan’s Syndrome
03/01/2021
A 25-year-old man came to our clinic with complaints of exertional palpitations and dyspnea. He had skeletal features suggestive of Marfan’s syndrome.
A 25-year-old man came to our clinic with complaints of exertional palpitations and dyspnea. He had skeletal features suggestive of Marfan’s syndrome.
A 25-year-old man came to our...
03/01/2021
Journal of Invasive Cardiology
Emergency Percutaneous Treatment of Saphenous Vein Graft Perforation After Cardiac Surgery
Emergency Percutaneous Treatment of Saphenous Vein Graft Perforation After Cardiac Surgery
03/01/2021
Acute saphenous vein graft perforation following coronary artery bypass graft surgery is rare. To the best of our knowledge, this is the first case report of acute saphenous vein graft perforation after coronary artery bypass graft surgery...
Acute saphenous vein graft perforation following coronary artery bypass graft surgery is rare. To the best of our knowledge, this is the first case report of acute saphenous vein graft perforation after coronary artery bypass graft surgery...
Acute saphenous vein graft...
03/01/2021
Journal of Invasive Cardiology
March 2021 Table of Contents
March 2021 Table of Contents
03/01/2021
March 2021 TOC and Whole Issue PDF
March 2021 TOC and Whole Issue PDF
March 2021 TOC and Whole Issue...
03/01/2021
Journal of Invasive Cardiology

News

AHA Scientific Statement
New American Heart Association Scientific Statement on Pulmonary Embolism Management & Outcomes
03/21/2025
A new scientific statement from the American Heart Association, Disparities in Current Pulmonary Embolism Management and Outcomes, summarizes differences in diagnosis, treatment strategies and long-term outcomes related to PE.
A new scientific statement from the American Heart Association, Disparities in Current Pulmonary Embolism Management and Outcomes, summarizes differences in diagnosis, treatment strategies and long-term outcomes related to PE.
A new scientific statement from...
03/21/2025
Cath Lab Digest
Therapeutics
Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
03/21/2025
The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
The approval expands the...
03/21/2025
Cath Lab Digest
TAVR
Medtronic’s Evolut Trial Outcome Could Shake Up US TAVR Market, Says GlobalData
03/21/2025
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
Medtronic has released results...
03/21/2025
Vascular Disease Management
SCAI
JSCAI Special Issue Explores the Transformative Role of Artificial Intelligence in Interventional Cardiology
03/18/2025
"AI is now an integral part of our daily lives, whether we are prepared for it or not. In medicine, particularly in interventional cardiology, its impact is profound,” said guest editor Elazer R. Edelman, MD, PhD.
"AI is now an integral part of our daily lives, whether we are prepared for it or not. In medicine, particularly in interventional cardiology, its impact is profound,” said guest editor Elazer R. Edelman, MD, PhD.
"AI is now an integral part of...
03/18/2025
Cath Lab Digest
Acquisitions
Ostial Corporation Becomes Verge Medical Following Strategic Acquisition
03/17/2025
Ostial Corporation, focused on addressing the clinical challenges of aorto-ostial interventions, announced the acquisition of the Wavella™ technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical.
Ostial Corporation, focused on addressing the clinical challenges of aorto-ostial interventions, announced the acquisition of the Wavella™ technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical.
Ostial Corporation, focused on...
03/17/2025
Cath Lab Digest
AltiX AI.i ComboLab
AI
GE HealthCare Expands Invasive Cardiology Portfolio With AltiX AI.i for Cath Lab and EP Procedures 
03/17/2025
The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features...
The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features...
The AltiX AI.i editions are...
03/17/2025
Cath Lab Digest
Heart Formation
New Hope for Heart Disease: Unlocking How the Heart Forms Before Birth
03/17/2025
Dr. Mingfu Wu and his team's findings, published in Science, focus on long, thin, channels of membranes – called Tunneling Nanotube-Like Structures - that connect cells together.
Dr. Mingfu Wu and his team's findings, published in Science, focus on long, thin, channels of membranes – called Tunneling Nanotube-Like Structures - that connect cells together.
Dr. Mingfu Wu and his team's...
03/17/2025
Cath Lab Digest
Out-of-Hospital Cardiac Arrest
ESC: Resuscitation in Out-of-Hospital Cardiac Arrest – It’s How Quickly It Is Done, Rather Than Who Does It
03/17/2025
The fact that 80% of out-of-hospital cardiac arrests (OHCA) occur in residential settings highlights the crucial need for further public education and Basic Life Support (BLS) training to improve survival rates.
The fact that 80% of out-of-hospital cardiac arrests (OHCA) occur in residential settings highlights the crucial need for further public education and Basic Life Support (BLS) training to improve survival rates.
The fact that 80% of...
03/17/2025
Cath Lab Digest
Heart Failure
U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
03/17/2025
KERENDIA® (finerenone) is the first non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) to meet a primary cardiovascular (CV) endpoint in a Phase III study investigating patients with heart failure (HF) with mildly reduced...
KERENDIA® (finerenone) is the first non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) to meet a primary cardiovascular (CV) endpoint in a Phase III study investigating patients with heart failure (HF) with mildly reduced...
KERENDIA® (finerenone) is the...
03/17/2025
Cath Lab Digest
CAD Diagnosis: AI
Caristo Diagnostics Receives U.S. FDA 510(k) Clearance of CaRi-Plaque Technology, an AI-assisted Image Analysis Application to Aid the Diagnosis of Coronary Artery Disease (CAD)
03/13/2025
CaRi-Plaque builds on Caristo’s breakthrough core CaRi-Heart® technology, which a landmark Lancet 2024 study proved can reveal hidden, high-risk markers of CAD progression — predicting heart attacks up to a decade before they strike.
CaRi-Plaque builds on Caristo’s breakthrough core CaRi-Heart® technology, which a landmark Lancet 2024 study proved can reveal hidden, high-risk markers of CAD progression — predicting heart attacks up to a decade before they strike.
CaRi-Plaque builds on Caristo’s...
03/13/2025
Cath Lab Digest

Endologix Announces 1000 Patients Treated With the DETOUR System
03/21/2025
Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to percutaneously bypass lesions in the superficial femoral artery by using stents routed through the...
Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to percutaneously bypass lesions in the superficial femoral artery by using stents routed through the...
Percutaneous Transmural Arterial...
03/21/2025
Cath Lab Digest
AHA Scientific Statement
New American Heart Association Scientific Statement on Pulmonary Embolism Management & Outcomes
03/21/2025
A new scientific statement from the American Heart Association, Disparities in Current Pulmonary Embolism Management and Outcomes, summarizes differences in diagnosis, treatment strategies and long-term outcomes related to PE.
A new scientific statement from the American Heart Association, Disparities in Current Pulmonary Embolism Management and Outcomes, summarizes differences in diagnosis, treatment strategies and long-term outcomes related to PE.
A new scientific statement from...
03/21/2025
Cath Lab Digest
Therapeutics
Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
03/21/2025
The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
The approval expands the...
03/21/2025
Cath Lab Digest
TAVR
Medtronic’s Evolut Trial Outcome Could Shake Up US TAVR Market, Says GlobalData
03/21/2025
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
Medtronic has released results from the two-year point of a clinical trial comparing its Evolut to Edwards Lifesciences’ SAPIEN. The results revealed that the Evolut showed superior performance to the SAPIEN. Specifically, the Evolut showed...
Medtronic has released results...
03/21/2025
Vascular Disease Management
SCAI
JSCAI Special Issue Explores the Transformative Role of Artificial Intelligence in Interventional Cardiology
03/18/2025
"AI is now an integral part of our daily lives, whether we are prepared for it or not. In medicine, particularly in interventional cardiology, its impact is profound,” said guest editor Elazer R. Edelman, MD, PhD.
"AI is now an integral part of our daily lives, whether we are prepared for it or not. In medicine, particularly in interventional cardiology, its impact is profound,” said guest editor Elazer R. Edelman, MD, PhD.
"AI is now an integral part of...
03/18/2025
Cath Lab Digest
ES image
CRT Conference Coverage
Future Direction for RDN: From Hypertension to AFib and Beyond
03/18/2025
In this video from CRT 2025, JIC speaks with Dr Eric Secemsky of the Beth Israel Deaconness Medical Center about the future of renal denervation in atrial fibrillation treatment.
In this video from CRT 2025, JIC speaks with Dr Eric Secemsky of the Beth Israel Deaconness Medical Center about the future of renal denervation in atrial fibrillation treatment.
In this video from CRT 2025, JIC...
03/18/2025
Journal of Invasive Cardiology
Acquisitions
Ostial Corporation Becomes Verge Medical Following Strategic Acquisition
03/17/2025
Ostial Corporation, focused on addressing the clinical challenges of aorto-ostial interventions, announced the acquisition of the Wavella™ technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical.
Ostial Corporation, focused on addressing the clinical challenges of aorto-ostial interventions, announced the acquisition of the Wavella™ technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical.
Ostial Corporation, focused on...
03/17/2025
Cath Lab Digest
AltiX AI.i ComboLab
AI
GE HealthCare Expands Invasive Cardiology Portfolio With AltiX AI.i for Cath Lab and EP Procedures 
03/17/2025
The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features...
The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features...
The AltiX AI.i editions are...
03/17/2025
Cath Lab Digest
Heart Formation
New Hope for Heart Disease: Unlocking How the Heart Forms Before Birth
03/17/2025
Dr. Mingfu Wu and his team's findings, published in Science, focus on long, thin, channels of membranes – called Tunneling Nanotube-Like Structures - that connect cells together.
Dr. Mingfu Wu and his team's findings, published in Science, focus on long, thin, channels of membranes – called Tunneling Nanotube-Like Structures - that connect cells together.
Dr. Mingfu Wu and his team's...
03/17/2025
Cath Lab Digest
Out-of-Hospital Cardiac Arrest
ESC: Resuscitation in Out-of-Hospital Cardiac Arrest – It’s How Quickly It Is Done, Rather Than Who Does It
03/17/2025
The fact that 80% of out-of-hospital cardiac arrests (OHCA) occur in residential settings highlights the crucial need for further public education and Basic Life Support (BLS) training to improve survival rates.
The fact that 80% of out-of-hospital cardiac arrests (OHCA) occur in residential settings highlights the crucial need for further public education and Basic Life Support (BLS) training to improve survival rates.
The fact that 80% of...
03/17/2025
Cath Lab Digest

March 2021 Volume 33 Issue 3

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use